Skip to main content
Nature Portfolio logoLink to Nature Portfolio
. 2022 Dec 28;4(1):148. doi: 10.1038/s43018-022-00507-6

Author Correction: A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC

Laurel B Darragh 1,2, Michael M Knitz 1, Junxiao Hu 3, Eric T Clambey 4, Jennifer Backus 1, Andrew Dumit 1, Von Samedi 5, Andrew Bubak 6, Casey Greene 3,7, Timothy Waxweiler 1, Sanjana Mehrotra 5, Shilpa Bhatia 1, Jacob Gadwa 1, Thomas Bickett 1, Miles Piper 1, Kareem Fakhoury 1, Arthur Liu 8, Joshua Petit 8, Daniel Bowles 9, Ashesh Thaker 10, Kimberly Atiyeh 11, Julie Goddard 12, Robert Hoyer 9, Adrie Van Bokhoven 5, Kimberly Jordan 2, Antonio Jimeno 9, Angelo D’Alessandro 7, David Raben 1, Jessica D McDermott 9, Sana D Karam 1,2,
PMCID: PMC9886545  PMID: 36577897

Correction to: Nature Cancer 10.1038/s43018-022-00450-6, published online 25 November 2022.

In the version of this article initially published, the Competing interests section was missing the disclosure “A.J. has research support from NCI R01CA149456, R01DE024371, and P50CA261605; and stock/options ownership in Suvica and Champions Oncology. A.J.’s institution has contracts with Cantargia, DebioPharm, Genentech, Iovance, Khar Biopharma, Merck, Moderna, Pfizer, Sanofi, and SQZ for trials where A.J. is the local P.I.” The error has been corrected in the HTML and PDF versions of the article.


Articles from Nature Cancer are provided here courtesy of Nature Publishing Group

RESOURCES